Canaccord Genuity Maintains Buy on Biodesix, Raises Price Target to $27

Benzinga Newsdesk www.benzinga.com Positive 83.1%

Neg 0% Neu 0% Pos 83.1%

Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $22 to $27.